InvestorsHub Logo
Followers 51
Posts 9111
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Wednesday, 04/12/2023 12:21:16 AM

Wednesday, April 12, 2023 12:21:16 AM

Post# of 13489
Moderna's mRNA flu shot struggles to prove its worth again in phase 3 trial.....relax!!!!!!

A preliminary analysis of immunogenicity from a subset of participants in the trial has also been completed, which showed that mRNA-1010 demonstrated geometric mean titer ratios suggesting it was more effective against both influenza A strains than an approved flu vaccine. However, when it came to both influenza B strains, the shot was only able to show “non-inferiority” to the competitor, Moderna said.

https://www.fiercebiotech.com/biotech/modernas-mrna-flu-shot-continues-struggle-prove-its-worth-phase-3-trials
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News